Hypera S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
October 26, 2023 at 06:15 pm EDT
Share
Hypera S.A. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was BRL 2,138.46 million compared to BRL 2,035.78 million a year ago. Net income was BRL 499.27 million compared to BRL 466.03 million a year ago. Basic earnings per share was BRL 0.79 compared to BRL 0.73 a year ago.
For the nine months, sales was BRL 6,067.73 million compared to BRL 5,424.96 million a year ago. Net income was BRL 1,342.43 million compared to BRL 1,268.85 million a year ago. Basic earnings per share was BRL 2.12 compared to BRL 2.01 a year ago.
Hypera (formerly Hypermarcas) is the Brazilian leader in the manufacture and marketing of pharmaceutical products. The products are sold primarily under the Addera D3, Adocyl, AdultMax, Alivium, Apracur, Atroveran, Benegrip, Bigfral, Biotonico Fontoura, Coristina, Cremer, Doril, Engov, Epocler, Lisador and Neo Quimica. The activity is organized around 3 families of products :
- OTC medicines;
- prescription medicines;
- branded generic medicines.
HYPERA S.A. 
